The Manufacturers Life Insurance Company Makes New $6.85 Million Investment in Lantheus Holdings, Inc. $LNTH

The Manufacturers Life Insurance Company bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 61,716 shares of the medical equipment provider’s stock, valued at approximately $6,847,000. The Manufacturers Life Insurance Company owned approximately 0.09% of Lantheus at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Reinhart Partners LLC. raised its holdings in Lantheus by 2.2% during the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after purchasing an additional 34,501 shares during the last quarter. Versor Investments LP purchased a new stake in Lantheus during the fourth quarter worth $519,000. M&T Bank Corp acquired a new stake in Lantheus in the fourth quarter valued at $539,000. Epoch Investment Partners Inc. increased its position in shares of Lantheus by 59.4% in the first quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock valued at $49,284,000 after buying an additional 242,222 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Lantheus by 440.3% in the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock valued at $79,320,000 after buying an additional 582,661 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on LNTH. CJS Securities downgraded Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. Leerink Partners set a $102.50 target price on shares of Lantheus in a report on Monday, August 3rd. Weiss Ratings upgraded shares of Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday. Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Truist Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating and lowered their price target for the company from $125.00 to $102.50 in a research report on Monday, August 3rd. Four analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $108.11.

Lantheus Price Performance

Lantheus stock opened at $100.77 on Monday. Lantheus Holdings, Inc. has a 12-month low of $49.67 and a 12-month high of $111.86. The stock has a market capitalization of $6.58 billion, a P/E ratio of 24.34 and a beta of -0.03. The firm’s 50-day moving average is $103.74 and its two-hundred day moving average is $91.76. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. The business had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.57 earnings per share. Equities analysts predict that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.